Résultats de la recherche
10
Tout
Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update
27 févr. 2025 16h10 HE
|
Merus N.V.
- Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC and petosemtamab monotherapy in 2/3L r/m HNSCC enrolling; expected to be substantially...
Merus to Present at Upcoming Investor Conferences
25 févr. 2025 08h00 HE
|
Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific...
Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma
18 févr. 2025 08h00 HE
|
Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific...
Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit
13 févr. 2025 08h00 HE
|
Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific...
New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer
05 févr. 2025 17h00 HE
|
Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative,...
Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC
16 déc. 2024 16h01 HE
|
Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific...
Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC
07 déc. 2024 01h30 HE
|
Merus N.V.
Petosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing HNSCC ongoing with clinical data update planned for 2025 Petosemtamab in mCRC evaluation expanded to include 1L and 3L+;...
Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study
04 déc. 2024 16h55 HE
|
Merus N.V.
BIZENGRI® is the first and only therapy approved by the FDA specifically for pancreatic adenocarcinoma and NSCLC that harbor NRG1 gene fusions and are advanced unresectable or metastatic1Merus and...
Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt
02 déc. 2024 08h00 HE
|
Merus N.V.
UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, das Unternehmen, wir oder unser), ein im klinischen Stadium tätiges...
Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive
02 déc. 2024 08h00 HE
|
Merus N.V.
UTRECHT, Pays-Bas et CAMBRIDGE, Massachusetts, 02 déc. 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS) (Merus, la Société, nous ou notre), une société du secteur de l’oncologie au stade...